Imposing Everolimus REMS On Sirolimus Rests On If There Is New Safety Info

The approval of Novartis' Zortress (everolimus) with a Risk Evaluation and Mitigation Strategy has opened up an FDA review of whether Pfizer's Rapamune (sirolimus), from which everolimus is derived, should have a similar plan